Health Care
featured
The health-care industry is looking to harness big data, but finding the right workers isn't always easy. In some cases, companies are making acquisitions to bring talent in-house.
» Read More
More
-
It's a new month. Time to clean out the inbox. Regarding my post earlier this week about Sen. Chuck Grassley's office breaking the "Nature" embargo on the leak of the GlaxoSmithKline Avandia study, I heard from the "Nature" article reporter.
-
A new merger and growth overseas make this stock a buy.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
-
I just got off the phone with the Chief Operating Officer of PR Newswire, Dave Armon, who says the discrepancy between the two Bristol-Myers Squibb earnings press releases I've been blogging about was due to an information technology glitch at PR Newswire.
-
Operating profit at Denmark's Novo Nordisk slipped 2 percent last year but still beat analysts' expectations due to strong sales growth in the US and China, company CEO Lars Rebien told "Worldwide Exchange" on Thursday.
-
This morning on "Squawk on the Street" I did a pharma earnings round-up report and I topped it by saying the sector could remain under pressure today because two major American drug companies--Bristol-Myers Squibb and Wyeth-- missed earnings expectations and lowered their 2008 guidance.
-
It's a booyah-free zone. There goes Swifty!Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
-
At 1 pm ET today the embargo was supposed to lift on an article in the scientific journal "Nature" that we got advanced word on early this morning. We were set to post the write-through about it at that time on our web site.
-
The scientific journal Nature reported today that a peer-reviewer for The New England Journal of Medicine leaked key study results on GlaxoSmithKline's diabetes drug Avandia to the company weeks before they were published.
-
Dow component Merck beat the Street with fourth quarter results on earnings per share (revenue was a sliver below the analyst consensus) and reaffirmed its earnings guidance for this year. Maybe the beaten-down stock is falling victim to another pre-Fed interest rate decision market downdraft...
-
"Dendreonians" were hoping the Provenge controversy might come up for discussion at the House Energy and Commerce Committee's Subcommittee on Oversight and Investigations hearing today.
-
Direct-to-consumer pharmaceutical advertising is everywhere in American media because it works. Generally speaking, it drives patients to ask/tell their doctors to prescribe a particular medication.
-
In what I would describe as a pretty extraordinary filing with the Securities and Exchange Commission, Schering-Plough is putting in black and white the date and time that senior level executives were informed about the results of the controversial ENHANCE study of the cholesterol drug Vytorin.
-
Friday I blogged about the most audacious press release I've received in a long time from a small biomed company called GenoMed. The company's Chairman and CEO, Dr. David Moskowitz, claims Heath Ledger probably died due to complications from the flu--likening it to Anna Nicole Smith's death--and GenoMed had the means to save him.
-
Allergan is best known for Botox and silicon, but now it's on the frontlines of curing a life-threatening disease. Not so skin deep anymore.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
-
A $4 billion company I've never covered before, Inverness Medical Innovations, is making news this morning with a $900 million acquisition of another company I've never covered--Matria Healthcare, Inc. But that's not why I'm blogging about Inverness.
-
I listened in to the hour-long Food and Drug Administration conference call with reporters regarding Vytorin, and I wanted to pass along a few highlights...
-
In the wake of my semantic disagreement with Amgen over whether it beat, met or missed its earnings pre-announcement earlier this month, analysts are putting out research notes to clients on the company's results, guidance and new drug data and blog readers are sending emails about my take on the full year 2007 number.
-
With the big swings in the market, we thought it would be interesting to see where the S&P Sectors stand from last year's highs. As expected, the defensive Consumer Staples and Health Care sectors have held up better than the bludgeoned Financial sector.
-
I just got back to my desk after doing a breaking news alert on Amgen's earnings. To sum up, I characterized the report as a mixed bag. The anemia drug sales weren't as bad as expected. Overall revenue was higher than consensus. And fourth quarter earnings per share was three cents higher than the Street.
-
Amgen reported on Thursday that its fourth-quarter profit edged higher, on a reversal of declining sales of its anemia drugs that have been hit with safety concerns and new restrictions on their use and insurance reimbursements.